Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
07 mai 2024 16h05 HE
|
Immuneering Corporation
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
Immuneering Recognizes Melanoma Awareness Month
06 mai 2024 16h30 HE
|
Immuneering Corporation
Immuneering Recognizes Melanoma Awareness Month
Immunocore announces upcoming presentation and posters at ASCO 2024
24 avr. 2024 10h00 HE
|
Immunocore Holdings plc
Immunocore announces upcoming presentation and posters at ASCO 2024 Phase 1 expansion data in immune checkpoints pre-treated cutaneous melanoma for brenetafusp (IMC-F106C targeting PRAME) to be...
[Latest] Global Pet Cancer Therapeutics Market Size/Share Worth USD 1,162.4 Million by 2033 at a 9.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
08 avr. 2024 13h30 HE
|
Custom Market Insights
Austin, TX, USA, April 08, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Pet Cancer Therapeutics Market Size, Trends and Insights By Therapy...
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
03 avr. 2024 16h05 HE
|
Immuneering Corporation
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
[Latest] Global Cancer Immunotherapy Market Size/Share Worth USD 314.4 Billion by 2032 at a 7.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
28 mars 2024 15h30 HE
|
Custom Market Insights
Austin, TX, USA, March 29, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Cancer Immunotherapy Market Size, Trends and Insights By Type of Immunotherapy...
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
27 mars 2024 08h00 HE
|
Immuneering Corporation
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
11 mars 2024 08h00 HE
|
Immuneering Corporation
- First patient dosed with IMM-1-104 in combination with modified gemcitabine plus nab-paclitaxel for first-line treatment of pancreatic ductal adenocarcinoma (PDAC) - - Phase 2a portion of Phase...
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
05 janv. 2024 07h00 HE
|
Immunocore Holdings Limited
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation Increasing commercial access to KIMMTRAK (tebentafusp-tebn)...
Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 07h00 HE
|
Immunocore Holdings Limited
Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 03 January, 2024) Immunocore Holdings plc...